View source for Mitral stenosis screening

__NOTOC__
{{Mitral stenosis}}

{{CMG}}; {{AE}} {{S.G.}}
==Overview==

According to the  2014 and 2017 AHA/ACC [[Medical guideline|Guideline]], screening for mitral stenosis by [[TTE]] is recommended among [[patients]] with [[Medical sign|signs]] or [[Symptom|symptoms]]. " [[Exercise stress testing|Exercise testing]] with [[Doppler]] or [[Invasive (medical)|invasive]] [[Hemodynamic assessment in the cardiac catheterization laboratory|hemodynamic assessment]] is recommended to evaluate the response of the mean [[Mitral valve|mitral]] [[gradient]] and [[pulmonary]] [[artery]] [[pressure]] in [[Patient|patients]] with MS when there is a discrepancy between resting [[Doppler]] [[echocardiographic]] findings and [[clinical]] [[Symptom|symptoms]] or [[Medical sign|signs]]".
==Screening==
According to the  2014 and 2017 AHA/ACC [[Medical guideline|Guideline]], screening for mitral stenosis by [[TTE]] is recommended among [[patients]] with [[Medical sign|signs]] or [[Symptom|symptoms]]. " [[Exercise stress testing|Exercise testing]] with [[Doppler]] or [[Invasive (medical)|invasive]] [[Hemodynamic assessment in the cardiac catheterization laboratory|hemodynamic assessment]] is recommended to evaluate the response of the mean [[Mitral valve|mitral]] [[gradient]] and [[pulmonary]] [[artery]] [[pressure]] in [[Patient|patients]] with MS when there is a discrepancy between resting [[Doppler]] [[echocardiographic]] findings and [[clinical]] [[Symptom|symptoms]] or [[Medical sign|signs]]".<ref name="NishimuraOtto2014">{{cite journal|last1=Nishimura|first1=Rick A.|last2=Otto|first2=Catherine M.|last3=Bonow|first3=Robert O.|last4=Carabello|first4=Blase A.|last5=Erwin|first5=John P.|last6=Guyton|first6=Robert A.|last7=O’Gara|first7=Patrick T.|last8=Ruiz|first8=Carlos E.|last9=Skubas|first9=Nikolaos J.|last10=Sorajja|first10=Paul|last11=Sundt|first11=Thoralf M.|last12=Thomas|first12=James D.|title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary|journal=Circulation|volume=129|issue=23|year=2014|pages=2440–2492|issn=0009-7322|doi=10.1161/CIR.0000000000000029}}</ref><ref name="NishimuraOtto2017">{{cite journal|last1=Nishimura|first1=Rick A.|last2=Otto|first2=Catherine M.|last3=Bonow|first3=Robert O.|last4=Carabello|first4=Blase A.|last5=Erwin|first5=John P.|last6=Fleisher|first6=Lee A.|last7=Jneid|first7=Hani|last8=Mack|first8=Michael J.|last9=McLeod|first9=Christopher J.|last10=O’Gara|first10=Patrick T.|last11=Rigolin|first11=Vera H.|last12=Sundt|first12=Thoralf M.|last13=Thompson|first13=Annemarie|title=2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines|journal=Circulation|volume=135|issue=25|year=2017|issn=0009-7322|doi=10.1161/CIR.0000000000000503}}</ref>

==References==
{{Reflist|2}}

{{WH}}
{{WS}}
[[Category: (name of the system)]]